Perseus Proteomics, Inc. (JP:4882) has released an update.
Perseus Proteomics Inc. has formed a partnership with Yamagata University, Osaka Metropolitan University, and Tokyo University of Agriculture and Technology to advance the development of multispecific antibodies. These engineered antibodies can target multiple molecules or cells simultaneously, which has potential applications in innovative cancer treatments. The collaboration aims to combine the Company’s diverse antibody library with cutting-edge biopharmaceutical design technologies.
For further insights into JP:4882 stock, check out TipRanks’ Stock Analysis page.
